(19)
(11) EP 2 044 066 A2

(12)

(88) Date of publication A3:
17.07.2008

(43) Date of publication:
08.04.2009 Bulletin 2009/15

(21) Application number: 07795829.6

(22) Date of filing: 06.06.2007
(51) International Patent Classification (IPC): 
C07D 417/14(2006.01)
A61K 31/427(2006.01)
A61P 31/00(2006.01)
(86) International application number:
PCT/US2007/013384
(87) International publication number:
WO 2007/146039 (21.12.2007 Gazette 2007/51)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK RS

(30) Priority: 06.06.2006 US 811482 P

(71) Applicant: Bristol-Myers Squibb Company
Princeton NJ 08543-4000 (US)

(72) Inventors:
  • GOUGOUTAS, Jack, Z.
    Princeton, NJ 08540 (US)
  • MALLEY, Mary, F.
    Lawrenceville, NJ 08648 (US)
  • DIMARCO, John, D.
    East Brunswick, NJ 08816 (US)
  • KIM, Soojin
    Demarest, NJ 07627 (US)
  • XIAO, Hai-yun
    Belle Mead, NJ 08502 (US)
  • MISRA, Raj, Narain
    Hopewell, NJ 08525 (US)

(74) Representative: Ritter, Thomas Kurt 
Jones Day Prinzregentenstraße 11
80538 München
80538 München (DE)

   


(54) CRYSTALLINE FORMS OF N-[5-[[[5-(1,1-DIMETHYLETHYL)-2-OXAZOLYL]METHYL] THIO]-2-THIAZOLYL]-4-PIPERIDINECARBOXAMIDE